5-羟色胺2A受体基因多态性与抑郁症的关联

目的：探讨中国汉族人群难治性抑郁症患者与5-羟色胺2A(5-HT2A)受体基因的T102C多态性之间的关系。方法：抽取79例难治性抑郁症患者作研究，以102名正常人作对照。应用聚合酶链式反应(PCR)扩增技术及限制性片段长度多态性(RFLP)分别测定所有研究对象的5-HT2A受体基因的基因型和等位基因。结果：5-HT2A受体基因的3种基因型(A1／A1，A1／A2和A2／A2)在难治性抑郁症组的分布分别为31．6％、54．4％和13．9％，在对照组分别为29．4％、45．1％和25．5％，两组间差异无显著性。结论：5-HB。受体基因的T102C多态性与难治性抑郁症之间无显著关联。     

中国北方汉族人群5-羟色胺2A受体基因的T102C多态性与重性抑郁症的关联研究

目的 探讨中国北方汉族人群重性抑郁症患者与5-羟色胺2A(5-HT2A)受体基因的T102C多态性之间的关系.方法 选取375例重性抑郁症患者作研究,以374名健康人作对照,应用聚合酶链式反应(PCR)扩增技术及直接测序法测定所有研究对象的5-HT2A受体基因T102C多态性的基因型和等位基因分布.结果 5-HT2A受体基因T102C多态性基因型和等位基因在患者组和对照组的分布差异无统计学意义(P>0.05);按照发病年龄(30岁为界)、有无家族史分层后,患者组与对照组间基因型和等位基因分布也无统计学意义(P>0.05).结论 未发现中国北方汉族人群5-HT2A受体基因T102C多态性与重性抑郁症存在关联.     

5—HT6受体基因多态性与阿尔茨海默病的关联分析

目的探讨中国上海地区汉族人群中5-HT6受体基因多态性与阿尔茨海默病(AD)的相互关系.方法应用聚合酶链式反应(PCR)-限制性片段长度多态性(RFLP)方法,在106例AD患者,87例血管性痴呆(VD)患者和140例正常健康人中观察了5-HT6受体基因多态性的分布,并对5-HT6受体基因多态性与阿尔茨海默病之间的关系进行探讨.结果①阿尔茨海默病与5-HT6受体基因的多态性之间无显著意义的关联(P＞0.05);②在将受试人群进行ApoE基因分型后,ApoEε4型与非ApoEε4型人群中AD与5-HT6受体基因各基因型或等位基因均无关联(P＞0.05);③将AD患者进行ApoE基因分型后,非ApoEε4型AD与5-HT6的267C/T基因型正相关(OR=2.46,95%CI5.43-1.11,P＜0.05).结论中国上海地区汉族人群中5-HT6受体基因多态性与非ApoEε4型阿尔茨海默病相关联,表现为C/T型频率的升高.     

5-HT2A受体基因T102C多态性与情感性精神障碍的关联研究

目的　探索 5 HT2A受体基因T10 2C多态性与情感性精神障碍易感性的关系。方法　采用限制性片断长度多态性与聚合酶链式反应 (PCR RFLP)分析技术 ,检测情感性精神障碍和正常对照组的 5 HT2A受体基因T10 2C多态性的基因型和等位基因频率。结果　情感障碍组和正常对照组、情感障碍组各亚型和正常对照组之间 5 HT2A受体基因T10 2C多态性基因型和等位基因频率的比较未发现显著性差异 ;不同性别、有无阳性家庭史、伴或不伴自杀企图的情感障碍病人的 5 HT2A受体基因T10 2C多态性的基因型和等位基因频率的比较未发现显著性差异。结论　 5 HT2A受体基因T10 2C多态性与情感性精神障碍缺乏关联 ,提示其可能不是该病的易感性因子。     

5-HT2c受体基因多态性与抗精神病药物疗效的关联分析

目的探讨5-HT2c受体基因-759C／T、-697G／C多态性与非典型抗精神病药物治疗首发精神分裂症患者疗效的关系。方法179例首发精神分裂症患者接受利培酮或氯氮平治疗8周,以PANSS量表评定患者的症状改善,以聚合酶链式反应（PCR）扩增及限制性片段长度多态性（RFLP）技术,检测5-HT2C受体基因-759C／T及-697G／C多态性。结果女性患者携带-759C等位基因的总疗效较-759T好,C／C基因型的阴性症状改善及总疗效优于C／T及T／T基因型,没有发现男性组和女性组697C／G各基因型与疗效存在关联。结论5-HT2。受体基因-759C／T基因多态性可能与非典型抗精神病药的疗效相关,C／C基因型和等位基因C可能是总体疗效好和阴性症状疗效好的预测因子。5-HT孙受体基因_1597G／C基因多态性可能与非典型抗精神病药的疗效无关。     

精神分裂症与5HT2a受体基因T102C多态性的关联研究

目的 探讨汉族人5-HT2a受体基因T102C多态性与精神分裂症病因之间的关系。方法 取223例精神分裂症病人作研究,以162例正常人作对照。用聚合酶链式反应(PCR)扩增及内切酶酶切技术测定所研究对象的基因型和等位基因。结果 发现精神分裂症与5-HT2a受体基因的基因型A1/A1关联。结论 5-HT2a受体基因T102C多态性与精神分裂症的易感性有关,基因型A1/A1是精神分裂症的风险因子。     

精神分裂症与5-羟色胺受体2A多态性相关性研究

目的 探测精神分裂症与5-HT2A受体基因多态性关系。方法用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）技术分析90例精神分裂症患者的5-HT2A受体（T102C）基因多态性，并以90例正常人作为对照。结果 在精神分裂症组和正常对照组中，等住基因A1、A2及基因型A1／A1、A1／A2、A2／A2的差异没有显著性（P〉0．05）。结论 本组样本中5-HT2A受体（T102C）基因多态性与精神分裂症无相关性。提示5-HT2A受体基因（T102C）突变可能不是导致精神分裂症发病的主要因素。     

5-HT2A受体基因102 T/C多态性与慢性抽动障碍的遗传关联

目的 探讨慢性抽动障碍与5-HT2A受体基因中102 T/C多态性的关系。方法 采用聚合酶链式反应(PCR)与限制性片段长度多态性(RFLPs)方法,对慢性抽动障碍儿童(n=72)与其亲生父母(n=131)的5-HT2A受体102 T/C的多态性分型,数据采用单体型相对风险(GHRR和HHRR)与传递不平衡检验(TDT)方法进行分析。 结果 合并焦虑情绪的慢性抽动障碍与5-HT2A受体102 T/C位点T等位基因存在关联或连锁不平衡(TDT 检验X2=5.45,P<0.05),而总的样本及其他分组与该位点无显著关联。 结论 5-HT2A受体102 T/C位点T等位基因与合并焦虑情绪的慢性抽动障碍相关联。     

5-HT_(2c)受体基因多态性与抗精神病药物疗效的关联分析

目的探讨5-HT2c受体基因-759C/T、-697G/C多态性与非典型抗精神病药物治疗首发精神分裂症患者疗效的关系。方法179例首发精神分裂症患者接受利培酮或氯氮平治疗8周,以PANSS量表评定患者的症状改善,以聚合酶链式反应(PCR)扩增及限制性片段长度多态性(RFLP)技术,检测5-HT2C受体基因-759C/T及-697G/C多态性。结果女性患者携带-759C等位基因的总疗效较-759T好,C/C基因型的阴性症状改善及总疗效优于C/T及T/T基因型,没有发现男性组和女性组697C/G各基因型与疗效存在关联。结论5-HT2c受体基因-759C/T基因多态性可能与非典型抗精神病药的疗效相关,C/C基因型和等位基因C可能是总体疗效好和阴性症状疗效好的预测因子。5-HT2c受体基因-697G/C基因多态性可能与非典型抗精神病药的疗效无关。     

同胞精神分裂症与5-羟色胺2A受体基因的关联分析

目的 探讨慢性精神分裂症患者的受累同胞和散发性精神分裂症与5-羟色胺2A受体基因(5-HT2A)T102C多态性的关联。方法 先用严格的纳入标准收集共患慢性精神分裂症的同胞60对(120例)和散发性精神分裂症120例,分别与正常同胞60对(120名)和120名正常人对照,采用聚合酶链反应(PCR)扩增及MspI内切酶酶切技术,检测各组的5-HT2A受体基因的基因型和等位基因的频率分布。结果 60对共患慢性精神分裂症的受累同胞组5-HT2A受体基因A1／A1基因型频率显著高于正常同胞组(X2=5.58,P<0.05),经配对比较,患者同胞组共有A1／A1基因型也显著多于正常同胞组(X2=3.94,P<0.05),而散发性精神分裂症与正常人对照组各基因型和等位基因的构成差异均无显著性意义。结论 共患慢性精神分裂症的同胞与5-HT2A受体基因A1／A1型关联,A1／A1纯合子易患精神分裂症,散发性精神分裂症可能与5-HT2A受体基因无关联。     

Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response

The serotonergic system is targeted by both antidepressants and atypical antipsychotic drugs such as clozapine. Genetic variation in the 5-HT5A gene might be involved in susceptibility to depression, the major psychoses or in influencing clinical response to treatment. To examine this hypothesis we genotyped two polymorphisms (-19G/C; 12A/T) in the human 5-HT5A receptor gene in a sample of 269 unrelated schizophrenic patients treated with clozapine, 112 bipolar patients, 75 unipolar patients and 187 controls. After five-fold correction for multiple testing, allelic association was found with the -19G/C polymorphism and bipolar affective disorder, (p = 0.025; OR 0.56), unipolar depression (p = 0.004; OR 0.52) and schizophrenia (p = 0.036; OR 0.67) indicating a potential protective effect of the G19 allele. For the 12A/T polymorphism allelic association was observed with unipolar depression only (p = 0.004). We conclude that allelic variation in the human 5-HT5A receptor gene may be involved in susceptibility to schizophrenia and affective disorders but not in determining response to clozapine.     

单相抑郁症与5-羟色胺2A受体基因多态性的关联研究

探讨中国汉族人群单相抑郁症患者与5－HT2A受体基因T102C多态性之间的关系，方法：采用AmP-RFLP方法，检测单相抑郁症患者对照组的5－HT2A受体基因频率分布。结果：单相抑郁症患者5－HT2A受体基因型频率，等位基因频率与对照组无明显差异。结论：本实验结果提示5－HT2A受体基因多态性与单相抑郁症患者未见明显相关，提示5－HT2A受体基因可能不是单相抑郁症发病的风险基因之一。     

No association between serotonin-2A receptor gene polymorphism and psychotic symptomatology of mood disorders.

Abnormalities of the serotonergic system are involved in the pathophysiology of mood disorders. In the present study, we investigated the possible influence of the T102C polymorphism of the serotonin-2A receptor gene (5-HT2A, 13q14-21) on the symptomatology of mood disorders. Inpatients affected by mood disorders (n = 246, 149 bipolar, 97 major depressive disorder) were assessed with a checklist of operational criteria for psychotic illness (OPCRIT) to score their lifetime psychotic symptomatology. The subjects were also typed for 5-HT2A variants using polymerase chain reaction techniques. No association was found between this polymorphism and psychopathology as defined by the four symptomatologic factors used in phenotype definition (mania, depression, delusion and disorganization). Genetic variation at the 5-HT2A receptor gene does not, therefore, appear to play a major role in the pathogenesis of major mood disorders.     

5—羟色胺2A受体基因多态性与精神分裂症阳性症状相关性研究

目的:探讨中国汉族人群精神分裂症阳性症状患者与5-羟色胺2A受体基因T102C多态性之间的关系.方法:采用AmP-RFLP方法,检测精神分裂症患者对照组的5-HT2A受体基因频率分布.结果:精神分裂症阳性症状患者5-HT2A受体基因型频率,等位基因频率与对照组无明显差异,但有精神病家族史精神分裂症患者A1A1基因型频率,A1等位基因频率明显高于对照组.结论:实验结果提示,5-HT2A受体基因多态性与有精神病家庭史的精神分裂症阳性症状患者密切相关.A1等位基因可能是精神分裂症发病的风险基因之一.     

5-HT1B基因A161T多态性与抑郁症的关联研究

目的探讨抑郁症患者与5-HT1B受体基因A161T多态性之间的关系。方法应用聚合酶链式反应（PCR）扩增技术及限制性片段长度多态性（arLP）分别检测365例抑郁症患者（病例组）、365名健康人（对照组）的5-HT1B受体基因A161T多态性。结果5-HT1B受体基因A161T多态性在病例组和对照组的基因型和等位基因分布频率无显著性差异；按照发病年龄（30岁为界）、有无家族史及有无自杀观念分层后，各亚组与对照组间基因型和等位基因分布也无显著性差异。经多因素分析控制年龄、性别因素后各组基因型分布仍无显著性差异。结论5-HT1B受体基因A161T多态性可能不是抑郁症及其各临床亚型发病的一个危险因素。     

癔症与5-HT2A受体基因T102C多态性的相关研究

目的 探讨中国汉族人群癔症患者与5-HT2A受体基因T102C多态性之间的关系。方法采用AmP-RFLP方法，检测癔症患者和对照组的5-HT2A受体基因频率。结果 5-HT2A受体基因多态性与癔症患者未见明显相关。结论 5-HT2A受体基因不是癔症发病的危险因素。     

Association of 5-HT(2A) receptor gene polymorphism with major affective disorders: the case of a subgroup of bipolar disorder with low suicide risk.

BACKGROUND: The implication of serotonin in suicide and affective disease explains why the 5-HT(2A) receptor gene has been proposed as a candidate gene in these disorders, although with conflicting results. METHODS: We analysed the distribution of the 5-HT(2A)-1438A/G genetic polymorphism in 192 patients with major affective disorder (127 bipolar disorders and 65 unipolar disorders) compared to 142 healthy control subjects. RESULTS: We found a higher frequency of the A allele in affected patients than in control subjects (p =.034), this difference being particularly striking for the subgroup of patients with type I bipolar disorder (p =.015). Patients with no personal and/or familial history of suicide attempts mainly accounted for the excess of the A allele in affected patients. CONCLUSIONS: The association detected in this study suggests that the 5-HT(2A) receptor gene may play a role in the genetic susceptibility to bipolar disorder, through a specific subgroup of bipolar type I patients with lower risk of suicidal behavior.     

Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease

BACKGROUND: Serotonin has been linked to neuropsychiatric symptoms in Alzheimer disease, mainly agitation/aggression, depression, and psychosis. Neuropsychiatric symptoms have been associated with polymorphisms of the promoter region (5-HTTPR ) and intron 2 of the serotonin transporter gene (5-HTTVNTR) or the 5-HT2A and 5-HT2C receptor genes in some but not all studies. OBJECTIVE: To examine the association of the serotonin promoter, transporter, and receptor genes with neuropsychiatric symptoms in patients with Alzheimer disease. METHODS: The sample included 96 patients with Alzheimer disease from the outpatient clinic of the University of California Los Angeles Alzheimer's Disease Research Center, Los Angeles. The Neuropsychiatric Inventory was used to measure neuropsychiatric symptoms, and blood samples were available for genetic analysis. Based on the literature, we hypothesized that the 5-HT2A and 5-HT2C receptor polymorphisms would be associated with agitation/aggression and psychosis and the 5-HTTPR or 5-HTTVNTR polymorphisms, with agitation/aggression or depression and anxiety. One-way analyses of variance were performed with age, ethnicity, sex, or education as covariates. RESULTS: The 102T genotype of the 5-HT2A receptor was significantly associated with delusions (P =.045) and agitation/aggression (P =.002). We did not replicate previous associations of the 5-HT2C receptor polymorphism with psychosis or of the 5-HTTPR polymorphism with agitation/aggression, psychosis, or depression. We did not find any associations with the 5-HTTVNTR polymorphism and agitation/aggression, depression, or anxiety. CONCLUSIONS: The 5-HT2A receptor polymorphism may contribute to the expression of psychosis and agitation/aggression in patients with Alzheimer disease. Absence of other positive associations may be due to the relatively small sample size and/or potentially small effect size of the polymorphisms and requires further study.